Rare Genetic Disorders
Palo Biofarma S.L. focuses on Prader-Willi syndrome, a complex rare genetic disorder associated with developmental, endocrine, and behavioural manifestations.
- Prader-Willi syndrome
- Genetic neurodevelopmental conditions
- Rare disease therapeutics
The sponsor’s clinical activity is centred on treatment options relevant to this orphan condition, reflecting interest in disorders with significant unmet medical need.
Neurodevelopmental and Behavioural Health
Its research interests extend to the neurological and behavioural dimensions of Prader-Willi syndrome, including areas linked to appetite regulation, cognition, and functional impairment.
- Neurodevelopmental impairment
- Behavioural symptoms
- Cognitive and functional outcomes
This area reflects attention to clinical features that affect daily functioning and long-term disease management.
Endocrine and Metabolic Disorders
The sponsor also works within endocrine and metabolic disease domains, where Prader-Willi syndrome presents with characteristic disturbances in weight regulation and hormonal balance.
- Metabolic dysregulation
- Hormonal abnormalities
- Weight and appetite control
These therapeutic interests align with clinical challenges commonly seen in patients requiring specialist care for multisystem disease.
Clinical Development in Orphan Medicine
Palo Biofarma S.L. is engaged in orphan drug development through a focused study program in a single rare disease setting, with attention to treatment safety, tolerability, and patient-relevant clinical outcomes.
- Orphan medicine
- Safety and tolerability
- Patient-centred rare disease care
Its clinical research activity is concentrated in Spain, with an emphasis on specialised therapeutic development for a narrowly defined patient population.
